Moving towards specific nutrigenetic recommendation algorithms: Caffeine, genetic variation and cardiovascular risk

Journal of Nutrigenetics and Nutrigenomics

Volumn 9, Issue 2-4, 2016, Pages 106-115

  De Caterina, Raffaele ^a   El Sohemy, Ahmed ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Caffeine; Cardiovascular disease; Coffee; Nutrigenetics; Recommendations

Indexed keywords

CAFFEINE; CYTOCHROME P450 1A2;

ALGORITHM; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; GENETIC VARIATION; HUMAN; PRIORITY JOURNAL; REVIEW; CARDIOVASCULAR SYSTEM; CONSENSUS DEVELOPMENT; DRUG EFFECTS; GENETICS; HEALTH CARE ORGANIZATION; NUTRIGENOMICS; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ALGORITHMS; BLOOD PRESSURE; CAFFEINE; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; GENETIC VARIATION; HUMANS; NUTRIGENOMICS; RISK FACTORS; SOCIETIES, SCIENTIFIC;

EID: 84982064110     PISSN: 16616499     EISSN: 16616758     Source Type: Journal    
DOI: 10.1159/000446801     Document Type: Review

References (60)

1. Aslam HM, Mughal A, Edhi MM, Saleem S, Rao MH, Aftab A, Hanif M, Ahmed A, Khan AM: Assessment of pattern for consumption and awareness regarding energy drinks among medical students. Arch Public Health 2013; 71: 31.
2. Fulgoni VL 3rd, Keast DR, Lieberman HR: Trends in intake and sources of caffeine in the diets of US adults: 2001-2010. Am J Clin Nutr 2015; 101: 1081-1087.
3. Higdon JV, Frei B: Coffee and health: a review of recent human research. Crit Rev Food Sci Nutr 2006; 46: 101-123.
4. Butt MS, Sultan MT: Coffee and its consumption: benefits and risks. Crit Rev Food Sci Nutr 2011; 51: 363-373.
5. Ludwig IA, Clifford MN, Lean ME, Ashihara H, Crozier A: Coffee: biochemistry and potential impact on health. Food Funct 2014; 5: 1695-1717.
6. Saab S, Mallam D, Cox GA 2nd, Tong MJ: Impact of coffee on liver diseases: a systematic review. Liver Int 2014; 34: 495-504.
7. Morisco F, Lembo V, Mazzone G, Camera S, Caporaso N: Coffee and liver health. J Clin Gastroenterol 2014; 48(suppl 1):S87-S90.
8. Schubert MM, Grant G, Horner K, King N, Leveritt M, Sabapathy S, Desbrow B: Coffee for morning hunger pangs. An examination of coffee and caffeine on appetite, gastric emptying, and energy intake. Appetite 2014; 83: 317-326.
9. Carman AJ, Dacks PA, Lane RF, Shineman DW, Fillit HM: Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease. J Nutr Health Aging 2014; 18: 383-392.
10. Sirtori CR, Galli C, Anderson JW, Sirtori E, Arnoldi A: Functional foods for dyslipidaemia and cardiovascular risk prevention. Nutr Res Rev 2009; 22: 244-261.
11. O'Keefe JH, Bhatti SK, Patil HR, DiNicolantonio JJ, Lucan SC, Lavie CJ: Effects of habitual coffee consumption on cardiometabolic disease, cardiovascular health, and all-cause mortality. J Am Coll Cardiol 2013; 62: 1043-1051.
12. Abdali D, Samson SE, Grover AK: How effective are antioxidant supplements in obesity and diabetes? Med Princ Pract 2015; 24: 201-215.
13. Ferruzzi MG: The influence of beverage composition on delivery of phenolic compounds from coffee and tea. Physiol Behav 2010; 100: 33-41.
14. Ribeiro JA, Sebastiao AM: Caffeine and adenosine. J Alzheimers Dis 2010; 20(suppl 1):S3-S15.
15. Robertson D, Froelich J, Carr K, Watson J, Hollifield J, Shand D, Oates J: Effects of caffeine on plasma renin activity, catecholamines and blood pressure. N Engl J Med 1978; 298: 181-186.
16. Lieberman HR: The effects of ginseng, ephedrine, and caffeine on cognitive performance, mood and energy. Nutr Rev 2001; 59: 91-102.
17. Riksen NP, Rongen GA, Smits P: Acute and long-term cardiovascular effects of coffee: implications for coronary heart disease. Pharmacol Ther 2009; 121: 185-191.
18. European Food Safety Authority (EFSA) Panel on Dietetic Products, Nutrition, and Allergies (NDA): Scientific opinion on the safety of caffeine. 2015. http://www.efsa.europa.eu/sites/default/files/consultation/150115. pdf?bcsi-scan-313cddce030931be=yIwqitE9o/ISyrpBzKjUCki1n3gBAAAAjORCAA==&bcsi-scan-filename=150115.pdf.
19. Colton T, Gosselin R, Smith R: The tolerance of coffee drinkers to caffeine. Clin Pharmacol Ther 1968; 9: 31-39.
20. Yang A, Palmer AA, de Wit H: Genetics of caffeine consumption and responses to caffeine. Psychopharmacology (Berl) 2010; 211: 245-257.
21. Rasmussen BB, Brix TH, Kyvik KO, Brosen K: The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 2002; 12: 473-478.
22. Sachse C, Brockmoller J, Bauer S, Roots I: Functional significance of a C-A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47: 445-449.
23. Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H: Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 2006; 295: 1135-1141.
24. Ongini E, Fredholm BB: Pharmacology of adenosine A2A receptors. Trends Pharmacol Sci 1996; 17: 364-372.
25. Alsene K, Deckert J, Sand P, de Wit H: Association between A2A receptor gene polymorphisms and caffeineinduced anxiety. Neuropsychopharmacology 2003; 28: 1694-1702.
26. Morisaki T, Gross M, Morisaki H, Pongratz D, Zollner N, Holmes EW: Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci USA 1992; 89: 6457-6461.
27. Feldman AM, Wagner DR, McNamara DM: AMPD1 gene mutation in congestive heart failure: new insights into the pathobiology of disease progression. Circulation 1999; 99: 1397-1399.
28. Happonen P, Voutilainen S, Salonen JT: Coffee drinking is dose-dependently related to the risk of acute coronary events in middle-Aged men. J Nutr 2004; 134: 2381-2386.
29. Snapir A, Heinonen P, Tuomainen TP, Alhopuro P, Karvonen MK, Lakka TA, Nyyssonen K, Salonen R, Kauhanen J, Valkonen VP, Pesonen U, Koulu M, Scheinin M, Salonen JT: An insertion/deletion polymorphism in the alpha2B-Adrenergic receptor gene is a novel genetic risk factor for acute coronary events. J Am Coll Cardiol 2001; 37: 1516-1522.
30. Xie HG, Kim RB, Stein CM, Gainer JV, Brown NJ, Wood AJ: Alpha1A-Adrenergic receptor polymorphism: association with ethnicity but not essential hypertension. Pharmacogenetics 1999; 9: 651-656.
31. Bengtsson K, Melander O, Orho-Melander M, Lindblad U, Ranstam J, Rastam L, Groop L: Polymorphism in the beta(1)-Adrenergic receptor gene and hypertension. Circulation 2001; 104: 187-190.
32. Brodde OE, Buscher R, Tellkamp R, Radke J, Dhein S, Insel PA: Blunted cardiac responses to receptor activation in subjects with Thr164Ile beta(2)-Adrenoceptors. Circulation 2001; 103: 1048-1050.
33. Liggett SB, Wagoner LE, Craft LL, Hornung RW, Hoit BD, McIntosh TC: The Ile164 2-Adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 1998; 102: 1534-1539.
34. Maqbool A, Hall AS, Ball SG, Balmforth AJ: Common polymorphisms of beta1-Adrenoceptor: identification and rapid screening assay. Lancet 1999; 353: 897.
35. Ranade K, Shue WH, Hung YJ, Hsuing CA, Chiang FT, Pesich R, Hebert J, Olivier M, Chen YD, Pratt R, Olshen R, Curb D, Botstein D, Risch N, Cox DR: The glycine allele of a glycine/arginine polymorphism in the beta2-Adrenergic receptor gene is associated with essential hypertension in a population of Chinese origin. Am J Hypertens 2001; 14: 1196-1200.
36. Ringel J, Kreutz R, Distler A, Sharma AM: The Trp64Arg polymorphism of the beta3-Adrenergic receptor gene is associated with hypertension in men with type 2 diabetes mellitus. Am J Hypertens 2000; 13: 1027-1031.
37. White HL, Maqbool A, McMahon AD, Yates L, Ball SG, Hall AS, Balmforth AJ: An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals at risk of coronary events. A WOSCOPS substudy. Eur Heart J 2002; 23: 1087-1092.
38. Kelsey RM, Alpert BS, Dahmer MK, Krushkal J, Quasney MW: Beta-Adrenergic receptor gene polymorphisms and cardiovascular reactivity to stress in Black adolescents and young adults. Psychophysiology 2010; 47: 863-873.
39. James JE: Critical review of dietary caffeine and blood pressure: a relationship that should be taken more seriously. Psychosom Med 2004; 66: 63-71.
40. Renda G, Zimarino M, Antonucci I, Tatasciore A, Ruggieri B, Bucciarelli T, Prontera T, Stuppia L, De Caterina R: Genetic determinants of blood pressure responses to caffeine drinking. Am J Clin Nutr 2012; 95: 241-248.
41. Happonen P, Voutilainen S, Tuomainen TP, Salonen JT: Catechol-O-methyltransferase gene polymorphism modifies the effect of coffee intake on incidence of acute coronary events. PLoS One 2006; 1:e117.
42. Robertson D, Wade D, Workman R, Woosley RL, Oates JA: Tolerance to the humoral and hemodynamic effects of caffeine in man. J Clin Invest 1981; 67: 1111-1117.
43. Lane JD, Adcock RA, Williams RB, Kuhn CM: Caffeine effects on cardiovascular and neuroendocrine responses to acute psychosocial stress and their relationship to level of habitual caffeine consumption. Psychosom Med 1990; 52: 320-336.
44. Whitsett TL, Manion CV, Christensen HD: Cardiovascular effects of coffee and caffeine. Am J Cardiol 1984; 53: 918-922.
45. Pincomb GA, Lovallo WR, Passey RB, Wilson MF: Effect of behavior state on caffeine's ability to alter blood pressure. Am J Cardiol 1988; 61: 798-802.
46. Cornelis MC, El-Sohemy A, Campos H: Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction. J Med Genet 2004; 41: 758-762.
47. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF: Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989; 86: 7696-7700.
48. Gu L, Gonzalez FJ, Kalow W, Tang BK: Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992; 2: 73-77.
49. Kalow W, Tang BK: The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993; 53: 503-514.
50. Castorena-Torres F, Mendoza-Cantu A, de Leon MB, Cisneros B, Zapata-Perez O, Lopez-Carrillo L, Salinas JE, Albores A: CYP1A2 phenotype and genotype in a population from the Carboniferous Region of Coahuila, Mexico. Toxicol Lett 2005; 156: 331-339.
51. Han XM, Ou-Yang DS, Lu PX, Jiang CH, Shu Y, Chen XP, Tan ZR, Zhou HH: Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics 2001; 11: 429-435.
52. Klag MJ, Wang NY, Meoni LA, Brancati FL, Cooper LA, Liang KY, Young JH, Ford DE: Coffee intake and risk of hypertension: the Johns Hopkins precursors study. Arch Intern Med 2002; 162: 657-662.
53. Winkelmayer WC, Stampfer MJ, Willett WC, Curhan GC: Habitual caffeine intake and the risk of hypertension in women. JAMA 2005; 294: 2330-2335.
54. Bertrand CA, Pomper I, Hillman G, Duffy JC, Micheli I: No relation between coffee and blood pressure. N Engl J Med 1978; 299: 315-316.
55. Lang T, Degoulet P, Aime F, Fouriaud C, Jacquinet-Salord MC, Laprugne J, Main J, Oeconomos J, Phalente J, Prades A: Relation between coffee drinking and blood pressure: analysis of 6,321 subjects in the Paris region. Am J Cardiol 1983; 52: 1238-1242.
56. Stensvold I, Tverdal A, Foss OP: The effect of coffee on blood lipids and blood pressure. Results from a Norwegian cross-sectional study, men and women, 40-42 years. J Clin Epidemiol 1989; 42: 877-884.
57. Palatini P, Ceolotto G, Ragazzo F, Dorigatti F, Saladini F, Papparella I, Mos L, Zanata G, Santonastaso M: CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. J Hypertens 2009; 27: 1594-1601.
58. Guessous I, Dobrinas M, Kutalik Z, Pruijm M, Ehret G, Maillard M, Bergmann S, Beckmann JS, Cusi D, Rizzi F, Cappuccio F, Cornuz J, Paccaud F, Mooser V, Gaspoz JM, Waeber G, Burnier M, Vollenweider P, Eap CB, Bochud M: Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hypertension. Hum Mol Genet 2012; 21: 3283-3292.
59. Zhou SF, Yang LP, Zhou ZW, Liu YH, Chan E: Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J 2009; 11: 481-494.
60. Cornelis MC, Byrne EM, Esko T, et al: Genome-wide meta-Analysis identifies six novel loci associated with habitual coffee consumption. Mol Psychiatry 2015; 20: 647-656.